Biotech

Selected news for the healthcare topic - Biotech, collected since 10/2017. This healthcare topic shares news with COVID-19, COVID-19 Vaccine, Pfizer, Coronavirus, Moderna and hundreds of others.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
1/22/2022 San Diego unemployment rate at 4.2% - The San Diego Union-Tribune sandiegouniontribune.com ... of 5 percent.Advertisement While construction, tourism, education and government sectors lost jobs at the end of the year, it was some of San Diego’s best paying jobs that added the most positions. Biotech work, architecture and engineering saw the biggest gains.There were 4,100 jobs added in December in professional and business services. Some of the gains were in scientific research and developmental services, up 1,700; architectural and ...
1/21/2022 Drug Discovery Market VALUATION TO BOOM THROUGH 2025 hitechnewsdaily.com ... Drug Discovery industry. It mentions their strategic initiatives and offers a brief about their business.Key Players in TheDrug Discovery Covers: Covance, Merck & Co., GenScript, Boehringer Ingelheim, INC, Novartis, Pfizer, Johnson and Johnson, Viva Biotech (Shanghai) Ltd., Evotec A.G., WIL Research Laboratories, Glaxosmithkline LLC, Roche Holding AG, IQVIA, Sanofi, AMRI Global, Eli Lily, Bayer AG, AstraZeneca PLC Drug Discovery can be split based on product types, major applications, and important ...
1/21/2022 India and Sri Lanka to Collaborate in Sci&Tech Areas Including Waste-water Technologies, Biotech, Sustainable Agriculture, Big Data Analytics and AI indianweb2.com India and Sri Lanka extended the existing S&T cooperation for 3 more years, with focus on new areas like waste-water technologies, biotech, sustainable agriculture, aerospace engineering, robotics, big data analytics, and artificial intelligence, as well as industrial collaborations at the India-Sri Lanka 5th Joint Committee on S&T Cooperation held on January 20, 2022."India and Sri Lanka have a great legacy of intellectual, cultural, and religious ...
1/21/2022 Krystal Biotech (NASDAQ:KRYS) Coverage Initiated at Bank of America etfdailynews.com Bank of America initiated coverage on shares of Krystal Biotech (NASDAQ:KRYS) in a report released on Tuesday morning, Analyst Ratings Network reports. The brokerage issued a buy rating and a $110.00 price objective on the stock.Other analysts have also issued research reports about the stock. Zacks Investment Research raised shares of Krystal Biotech from a hold rating to a buy rating and set a $72.00 price target on ...
1/21/2022 Brickell Biotech (NASDAQ:BBI) Earns Buy Rating from Analysts at HC Wainwright - The Cerbat Gem thecerbatgem.com HC Wainwright began coverage on shares of Brickell Biotech (NASDAQ:BBI) in a report issued on Tuesday, Analyst Ratings Network reports. The brokerage issued a buy rating and a $2.00 price target on the stock.Shares of BBI stock opened at $0.26 on Tuesday. The company has a market cap of $29.92 million, a price-to-earnings ratio of -0.42 and a beta of -0.08. The stock has a 50 ...
1/21/2022 Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices — United States, December 2021 globaldiasporanews.com Photo credit: DiasporaEngager ( www.DiasporaEngager.com ).On February 27, 2021, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the adenovirus-vectored COVID-19 vaccine (Janssen Biotech , Inc., a Janssen Pharmaceutical company, Johnson & Johnson), and on February 28, 2021, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for its use as a single-dose primary vaccination in persons aged ≥18 years (1,2). On April ...
1/21/2022 Innate Pharma (NASDAQ:IPHA) Upgraded to “Buy” by Zacks Investment Research - Mayfield Recorder Mayfield Recorder ... rating to a buy rating in a report released on Thursday, Zacks.com reports. They currently have $5.00 price target on the stock.According to Zacks, “Innate Pharma S.A. is a commercial stage oncology-focused biotech company. It discovers and develops therapeutic antibodies for the treatment of cancer. The company’s commercial-stage product includes Lumoxiti. Innate Pharma S.A. is based in Marseille, France. “Get Innate Pharma alerts: IPHA has ...
1/21/2022 Molecular Partners (NASDAQ:MOLN) Lowered to “Hold” at Zacks Investment Research baseballnewssource.com Zacks Investment Research lowered shares of Molecular Partners (NASDAQ:MOLN) from a buy rating to a hold rating in a report released on Thursday morning, Zacks.com reports.According to Zacks, “Molecular Partners AG is a clinical-stage biotech company. It involved in developing a new class of custom-built protein drugs known as DARPin(R) therapeutics. Molecular Partners AG is based in SWITZERLAND. “Other analysts have also issued reports ...
1/21/2022 Innate Pharma (NASDAQ:IPHA) Lifted to “Buy” at Zacks Investment Research - Slater Sentinel slatersentinel.com ... a buy rating in a research note released on Thursday, Zacks.com reports. The brokerage currently has $5.00 price target on the stock.According to Zacks, “Innate Pharma S.A. is a commercial stage oncology-focused biotech company. It discovers and develops therapeutic antibodies for the treatment of cancer. The company’s commercial-stage product includes Lumoxiti. Innate Pharma S.A. is based in Marseille, France. “Get Innate Pharma alerts: Several other ...
1/21/2022 Swoon in Tech Stocks Puts Startup Valuations in Harsh New Light The Wall Street Journal ... year hit stratospheric levels.The public arenas have begun to dial down their fervor for high-growth tech stocks, with investors in particular punishing companies that don’t make money —startups in tech and biotech , blank-check companies and others still finding their feet ...
1/21/2022 Mirati's adagrasib spurs 41% response in pancreatic, GI tumors, scoring points where KRAS leader Amgen hasn't gone FierceBiotech Mirati Therapeutics' KRAS drug adagrasib led to a 41% response rate in patients with pancreatic and other gastrointestinal tumors, the latest in the biotech 's efforts to eke out an edge against the big winner in the drug class, Amgen.Rival Amgen beat Mirati into the KRAS-inhibitor market with Lumakras, which was approved in non-small cell lung cancer last May . Mirati is awaiting an FDA approval for adagrasib in ...
1/21/2022 Psychedelic biotech Eleusis enters SPAC deal to take depression drug to the clinic - MedCity News MedCity News ... than optimal outcomes. In a turnabout from the push for more oral depression drugs, Eleusis is developing an infused formulation of psilocybin that the company says could overcome limitations of oral psilocybin. As the biotech prepares for the first test of its drug in humans, it has signed a merger deal that infuses it with $288 million.Eleusis, which maintains operations in London and New York, announced Thursday that it ...
1/21/2022 Kura Oncology leukemia clinical trial to resume after FDA lifts partial hold - MedCity News MedCity News ... the company reached an agreement with the FDA on measures to guard against a particular complication.Kura announced the lift of the partial hold after the market close on Thursday. The San Diego-based biotech may now resume screening patients for the Phase 1b study, which is designed to find the appropriate dose to test in Phase 2.The Kura drug, KO-539, is being evaluated as a treatment for ...
1/21/2022 Top Biotech Stocks To Buy Now? 5 For Your Late January Watchlist | Nasdaq Nasdaq Here Are 5 Biotech Stocks To Check Out In The Stock Market Today As we move into the rest of 2022, it seems that biotech stocks could continue to be a viable play in the stock market. This can be attributed to the ongoing coronavirus concerns fueling the booming industry. Now, as the Omicron variant sweeps the globe, it shouldn’t come as a surprise as many investors continue to ...
1/21/2022 Amgen (AMGN) Stock Moves -1.04%: What You Should Know Nasdaq ... the S&P 500's 1.1% loss on the day. At the same time, the Dow lost 0.89%, and the tech-heavy Nasdaq gained 0.03%.Prior to today's trading, shares of the world's largest biotech drugmaker had gained 4.41% over the past month. This has outpaced the Medical sector's loss of 7.84% and the S&P 500's loss of 1.81% in that time.Investors will be hoping for strength ...
1/21/2022 The truth behind Silicon Valley's obsession with immortality vnexplorer.net ... fortune on, revealed that it has poached Hal Barron, 59, one of the world’s most respected scientists , to be its chief executive. That alone shows Altos means business – but the Silicon Valley biotech start-up also revealed $3 billion in funding and added a board of directors brimming with Nobel laureates.Death, the real final frontier, is much colder and darker than space. So Bezos, 57, is taking ...
1/21/2022 Why Novavax Stock Tumbled on Thursday | Nasdaq Nasdaq What happened Coronavirus stock Novavax (NASDAQ: NVAX) was a bit sickly on Thursday. The biotech 's shares declined by just over 2% on the day, a steeper fall than that suffered by the S&P 500 index. While the company had some good news to report, it wasn't enough to move the stock price upward.So what The latest development comes from over the Pacific Ocean, specifically Australia. After market hours ...
1/21/2022 Moderna stock fell to ‘overly high expectations:’ Jefferies Managing Director bitcoinethereumnews.com ... has slumped as of late — down around 60% from a September 2021 high of nearly $450.According to Jefferies’ (JEF) Michael Yee, managing director covering health-care equity research, the pharma and biotech company’s stock is in a rut due to not being able to meet the market’s expectations.“What I think in 2022 is that the overly high expectations and significant valuation is going to ...
1/21/2022 Quidel Has Strong Q4, COVID Tests in Demand sdbj.com ... million, with COVID-19 products generating $678 million in revenue. Quidel released its full financial results for 2020 in mid-February. Annual Sales Just Shy of $1.7 Billion In its Jan. 6 announcement, the biotech said it expects total revenues for 2021 to be slightly less than $1.7 billion (specifically, in the range of $1,695 million to $1,699 million). That compares with $1.66 billion in 2020. “We continue to work ...
1/21/2022 COVID Vaccines/Therapeutics – Developer/Manufacturer Announcements centerforvaccineethicsandpolicy.net ... data from ongoing trial showed increased antibody response against Beta, Delta, Alpha and Gamma variants following third dose booster with Vaxzevria:: Additional analysis showed increased antibody response to Omicron after a third doseBharat Biotech https://www.bharatbiotech.com/press_releases.html – No new digest announcements identifiedBioCubaFarma – CubaÚltimas Noticias13 de Enero, 2022Más del 82% de la población cubana completó su esquema de vacunación.[More ...